We are thrilled to announce that we have entered into a #research collaboration and license agreement with Astellas Pharma to pursue novel solid tumor targeted allogeneic #celltherapy treatments with the #capacitytocure in #oncology. See our #news release for details: https://lnkd.in/e7eHRGBS
Poseida Therapeutics, Inc.
Biotechnology Research
San Diego, California 36,280 followers
The Capacity to Cure
About us
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies as well as in-house cell therapy manufacturing. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients with hematological malignancies. Learn more at www.poseida.com.
- Website
-
http://poseida.com/
External link for Poseida Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2014
- Specialties
- Genome Engineering, CAR-T cells, Gene Therapy, Gene Editing, Cell Therapy, Adoptive Cell Therapy, Multiple Myeloma, Prostate Cancer, Transposon, Non-viral, Biotechnology, Immunotherapy, Regenerative Medicine, T-cells, Allogeneic, Oncology, Immuno-oncology, Immunology, Poseida, Cytotoxic T Lymphocytes, piggyBac®, piggyBac® DNA Modification System, Cas-CLOVER™, and TAL-CLOVER™
Locations
-
Primary
Get directions
9390 Towne Centre Dr
200
San Diego, California 92121, US
Employees at Poseida Therapeutics, Inc.
Updates
-
Kristin Yarema, Ph.D., our CEO, will speak at the 6th Annual Allogeneic Cell Therapies Summit in Boston tomorrow. She'll join an Industry Leaders Fireside Chat to highlight #allogeneic therapy wins and discuss #research advancements. She will also be presenting on Poseida’s lead allogeneic program, P-BCMA-ALLO1, in development for #patients with relapsed/refractory multiple myeloma. Learn more about the event here: https://lnkd.in/eF3cfef #CapacitytoCure #celltherapy #geneticmedicines
-
-
You do not want to miss this exciting panel at #BIO2024 in San Diego! Our CEO, Kristin Yarema, Ph.D., and other #oncology innovators will discuss #allogeneic cell therapy as the next generation of #cancer treatment. This discussion on June 6 will explore the promise of allo cell therapies to broaden patient access, lower costs, improve scalability and increase reliability. Learn more here: https://lnkd.in/ecmPGw8C #thefutureisallo #CapacitytoCure #geneticmedicines Biotechnology Innovation Organization
-
-
We are honored to be named one of Genetic Engineering & Biotechnology News' top 10 publicly owned gene editing therapy companies! Our focus on fully non-viral #allogeneic cell therapies and #geneticmedicines is driving promising progress across Poseida and our industry. Read more here: https://lnkd.in/e5iWd6Sc #CapacitytoCure #genetherapy
-
-
Every 27 seconds, someone faces a blood cancer diagnosis. On World Blood Cancer Day, Poseida stands with patients and caregivers and remain focused on advancing non-viral #allogeneic CAR-T cell therapy programs for the treatment of #multiplemyeloma and B-cell malignancies. #MakeYourMark #WBCD #CapacitytoCure
-
-
Today, we remember and honor the brave men and women who made the ultimate sacrifice for our nation. Their courage, dedication, and selflessness will never be forgotten. #MemorialDay #HonorOurHeroes #NeverForget
-
-
Be sure to find us at #ISCT24 in Vancouver on May 30 when we will present on product timelines and #allogeneic #celltherapy process development. All details available below and registration available here: https://lnkd.in/eYEcNEKg #CapacitytoCure ISCT, International Society for Cell & Gene Therapy
-
-
Our CEO, Kristin Yarema, Ph.D., will be joining an exciting panel of innovators at #BIO2024 in San Diego on June 6. Join this important discussion on #allogeneic #celltherapy as the future paradigm for #oncology treatment, with the promise to broaden patient access, lower costs, and increase reliability and scalability. All details out now: https://lnkd.in/ecmPGw8C #CapacitytoCure George Eastwood | Cokey Nguyen | Phuong Khanh (PK) Morrow | Abigail Jenkins | BIO International Convention
-
-
Want to explore #allogeneic #celltherapy manufacturing, donor comparability, screening and more? Our COO, Loren Wagner, speaks to Cell & Gene about how Poseida is solving for the future. Watch the replay: https://lnkd.in/d_ndrjKK #CapacitytoCure #CART
-
-
Did you know that Hereditary Angioedema (HAE) is a rare genetic condition causing painful and sometimes severe swelling in various parts of the body? Today, Poseida is raising awareness about this devastating disease. We are committed to advancing P-KLKB1-101, our investigational non-viral gene editing approach, and genetic engineering technologies to treat HAE. #CapacitytoCure #genetherapy #HereditaryAngioedema #HAEDay Hereditary Angioedema Association - HAEA